Print this page
-
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy.
Protocol: 032310Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Other -
NCI 10204 - A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Protocol: 092305Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers Big Ten Cancer Research Consortium BTCRC-GI22-564
Protocol: 072401Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Small Intestine -
Individual Patient Expanded Access for treatment of IDH-1 or IDH2-mutated glioma.
Protocol: 142401Principal Investigator:
- Vincent Yeung (Rutgers Cancer Institute of New Jersey-University Hospital)
Applicable Disease Sites: Brain and Nervous System -
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus
Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in
Patients With Previously Untreated Chronic Lymphocytic Leukemia
Protocol: 022401Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other -
A First-in-Human Study of Mutant-selective PI3K alpha; Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast